MedPath

Bladder preservation therapy with GC radiation against invasive bladder cancer.

Not Applicable
Conditions
Muscle-invasive bladder cancer
Registration Number
JPRN-UMIN000006363
Lead Sponsor
Department of Urology, Yamaguchi University, School of Medicine
Brief Summary

Chemoradiotherapy using gemcitabine and cisplatin for muscle-invasive bladder cancer is effective for local cancer control and shows no significant difference in oncological prognosis compared with radical cystectomy.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
38
Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients who have contraindication against gemcitabine and/or cisplatin. 2 Patients who received previous irradiation to pelvis. 3 Others, patients who have unsuitable condition.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence-free survival rate
Secondary Outcome Measures
NameTimeMethod
Disease-specific survival rate Overall survival rate Incidence of adverse events
© Copyright 2025. All Rights Reserved by MedPath